Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported.
BIOXYTRAN, INC. (OTCQB:BIXT), announced today that it intends to internally develop a novel carbohydrate Galectin inhibitor as opposed to licensing in ...
Satisfied Users & 
Approved Press Releases
